Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Cost of Revenue (2017 - 2025)

Historic Cost of Revenue for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $12.2 million.

  • Puma Biotechnology's Cost of Revenue fell 5816.41% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.0 million, marking a year-over-year decrease of 3456.27%. This contributed to the annual value of $64.4 million for FY2024, which is 274.72% up from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Cost of Revenue is $12.2 million, which was down 5816.41% from $12.3 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Cost of Revenue registered a high of $29.6 million during Q1 2021, and its lowest value of $10.3 million during Q3 2021.
  • Over the past 5 years, Puma Biotechnology's median Cost of Revenue value was $12.3 million (recorded in 2025), while the average stood at $14.8 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 22566.11% in 2021, then crashed by 6331.16% in 2022.
  • Puma Biotechnology's Cost of Revenue (Quarter) stood at $11.9 million in 2021, then skyrocketed by 41.54% to $16.8 million in 2022, then skyrocketed by 44.47% to $24.3 million in 2023, then plummeted by 42.77% to $13.9 million in 2024, then dropped by 12.56% to $12.2 million in 2025.
  • Its Cost of Revenue stands at $12.2 million for Q3 2025, versus $12.3 million for Q2 2025 and $10.6 million for Q1 2025.